Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page
- Check7 days agoNo Change Detected
- Check13 days agoChange DetectedAdded Revision: v3.4.2. Deleted the government funding lapse notice and related operating-status information (Revision: v3.4.1).SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a site-wide notice about funding-related status and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedThe changes are minor UI and metadata updates, including a glossary toggle, updated QC-related labels such as 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', and removal of older labels. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now shows Revision: v3.3.4, replacing Revision: v3.3.3. This appears to be a standard version update.SummaryDifference0.1%

- Check63 days agoChange DetectedA unified Locations section has been added, listing Connecticut and Texas. The prior separate Connecticut Locations and Texas Locations sections were removed.SummaryDifference0.3%

- Check92 days agoChange DetectedSite revision note shows v3.3.2 added and v3.2.0 removed, indicating a minor update to the platform. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.